Abstracts tagged "Systemic sclerosis"

Abstract Number: 0649 • ACR Convergence 2023
Early Systemic Sclerosis Definitions: Time to Rethink ‘Early’ in SSc Disease?
Francesco Del Galdo¹, Matthew Woods², Mario Ehlers³ and Stefano Di Donato¹, ¹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ²Lumanity, Manchester, United Kingdom, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune fibrotic disease with highly variable type and severity of organ involvement. Pathological changes in the skin, lungs,…
Abstract Number: 0671 • ACR Convergence 2023
Decreased Odds of Malignancy with Mycophenolate Use in a Single-Center Scleroderma Cohort
Jin Feng¹, Chrisanna Dobrowolski², Celestine He², Hannah Verma³, Roshan Vasoya³, Daniel Qian³, Ezequiel olumuyide³, Alicia Leong³, Joseph Menand¹, Murilo Roberto Bastos Silva¹, Vincent Courant¹ and Sophia Lutgen¹, ¹Icahn School of Medicine at Mount Sinai Morningside and West, New York, NY, ²Icahn School of Medicine at Mount Sinai Hospital, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Prior studies have shown an increased risk of malignancy in patients with systemic sclerosis (SSc). The reasons for this increased risk may be multifactorial,…
Abstract Number: 0944 • ACR Convergence 2023
Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis
Chanhyuk Park, Helen Jarnagin, Michael Whitfield and Patricia Pioli, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Autoimmune systemic sclerosis (SSc) is characterized by inflammation, vasculopathy, and dermal and internal organ fibrosis. A widely-reported but poorly understood aspect of SSc skin…
Abstract Number: 1232 • ACR Convergence 2023
Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Brian Feldman⁶, Maria Teresa TErreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Simone Appenzeller¹⁰, Edoardo Marrani¹¹, Maria Katsikas¹², Maria Jose Santos¹³, FLAVIO SZTAJNBOK¹⁴, Lillemor Berntson¹⁵, Juergen Brunner¹⁶, Sindhu Johnson¹⁷, Mikhail Kostik¹⁸, Kirsten Minden¹⁹, Farzana Nuruzzaman²⁰ and Nicola Helmus²¹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁵University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷UNIFESP, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ⁹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of Florence, Firenze, Italy, ¹²Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ¹³Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹⁴UFRJ/UERJ, São Paulo, Brazil, ¹⁵Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ¹⁶Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹⁷Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ¹⁸Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁹Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ²⁰Stony Brook Children's Hospital, Stony Brook, NY, ²¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1, 000, 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 1664 • ACR Convergence 2023
Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis
Minghua Wu¹, Jerry Alonso², Julio charles², Brian Skaug², Tingting Mills³, Maureen Mayes² and Shervin Assassi⁴, ¹Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ³Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, ⁴University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: A prominent interferon (IFN) activation signature has been observed at the peripheral blood and end-organ levels in systemic sclerosis (SSc). However, the mechanisms by…
Abstract Number: 2357 • ACR Convergence 2023
The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Itzchak Amoyal¹, Tzipi Hornik-Lurie², Tali Zitman-Gal¹, Hilit Levy³, Ilan Vaknin³, Liat Drucker⁴, Ishai Heusler⁵, Yair Levy¹ and Shelly Tartakover Matalon¹, ¹Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ²Meir Medical Center, Data Research Department, Kfar-Saba, Israel, ³Chemomab Ltd, Tel Aviv, Israel, ⁴Meir Medical Center, Oncogenetics Laboratory, Kfar Saba, Israel, ⁵Meir Medical Center, Department of Obstetric and Genecology, Kfar-Saba, Israel
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs. Endothelial cells (ECs),…
Abstract Number: 0611 • ACR Convergence 2023
Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Michael Hughes³, Julie Paik⁴, Christopher Mecoli², Laura Hummers⁴, Ami Shah⁵, Fred Wigley⁶ and Zsuzsanna McMahan⁷, ¹University of California Los Angeles, Los Angeles, CA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁶Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, ⁷Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: The gastrointestinal (GI) tract is the second most commonly affected organ in patients with systemic sclerosis (SSc). It is estimated that the small bowel…
Abstract Number: 0628 • ACR Convergence 2023
Interstitial Lung Disease in Very Early Systemic Sclerosis
Sinziana Muraru¹, Carina Mihai¹, Anna-Maria Hoffmann-Vold², Cosimo Bruni¹, Muriel Elhai³, Mike Becker⁴, Suzana Jordan¹, Alexandru Garaiman¹, Oliver Distler¹ and Rucsandra Dobrota¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) affects around 50% of patients with systemic sclerosis (SSc) and is the main cause of mortality. Preliminary data from small…
Abstract Number: 0650 • ACR Convergence 2023
Understanding the Employment Landscape in People with Systemic Sclerosis
Hila Jazayeri¹, Zareen Ahmad¹, Monique Gignac² and Sindhu Johnson³, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Work & Health, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic rheumatic disease that restricts participation in various life roles, including in the workplace. Our objectives were to identify…
Abstract Number: 0672 • ACR Convergence 2023
Risk of New-onset Depression in Patients with Systemic Sclerosis : A Nationwide Population-based Study
Hahee Son and Su-Jin Moon, Yeouido St. Mary's Hospital, Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic sclerosis (SSc) is a rare chronic inflammatory disease characterized by vasculopathy, autoimmunity and progressive fibrosis in various organs. The patients with SSc are…
Abstract Number: 0946 • ACR Convergence 2023
Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier¹, Clément Chauvet¹, Lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi¹, David Launay¹, Michel Salzet² and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³CHU Lille, Institut d’Immunologie, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
Abstract Number: 1233 • ACR Convergence 2023
The Pattern of Medication Use Significantly Changed over 36 Months Observation Period. Result from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Brian Feldman⁵, Kathryn Torok⁶, Maria Teresa TErreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Simone Appenzeller¹⁰, Edoardo Marrani¹¹, Maria Jose Santos¹², FLAVIO SZTAJNBOK¹³, Lillemor Berntson¹⁴, Juergen Brunner¹⁵, Mikhail Kostik¹⁶, Farzana Nuruzzaman¹⁷ and Nicola Helmus¹⁸, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷UNIFESP, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ⁹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of Florence, Firenze, Italy, ¹²Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹³UFRJ/UERJ, São Paulo, Brazil, ¹⁴Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ¹⁵Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹⁶Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁷Stony Brook Children's Hospital, Stony Brook, NY, ¹⁸Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently no medications are licensed for the treatment…
Abstract Number: 1665 • ACR Convergence 2023
Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis
Hanlin Yin¹, Oliver Distler², Bin Li³, Qingran Yan⁴ and Liangjing Lu¹, ¹Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Shanghai institute of immunology, Shanghai, China, ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiaotong Univeisty School of medcine, Shanghai, China
Background/Purpose: Type I interferon (IFN-1) signature is a hallmark of patients with systemic sclerosis (SSc). However, its significance in clinical stratification and contribution to deterioration…
Abstract Number: 2359 • ACR Convergence 2023
Reversal of the Activation State of Pro-fibrotic CD206 Positive Macrophages by Therapeutic Peptide AUR300 in Systemic Sclerosis
Sandra Lopez¹, Bahja Ahmed Abdi¹, Linda Lei¹, Anas Al-Oweidi¹, Claire Macfadyen¹, Lydia Nagib¹, Sarah Ive¹, Anshul Kumar¹, Teresa Collins¹, Jennifer Cross², Christopher Denton¹, David Abraham¹, Clayton Yates³, Charles Garvin⁴, Henry Lopez⁴, George Martin⁵ and Richard Stratton¹, ¹University College London, London, United Kingdom, ²Aurinia Pharmaceuticals Inc., Rockford, MD, ³Tuskegee University, Tuskegee, AL, ⁴Riptide Bioscience Inc., Valejo, CA, ⁵Riptide Bioscience Inc., Bethesda, MD
Background/Purpose: A spectrum of macrophage activation is seen in human pathologic conditions; M2-like CD206 positive macrophages are pro-fibrotic and proresolution, while M1-like macrophages are proinflammatory,…
Abstract Number: 0612 • ACR Convergence 2023
COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study
Kimberly Lakin¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier², Richard Henry², Christopher Denton⁴, Luc Mouthon⁵, Robert Spiera⁶ and Brett Thombs², ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ³Radboud University, Nijmegen, Netherlands, ⁴University College London, London, United Kingdom, ⁵Hopital Cochin - Paris University, Paris, France, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: We previously surveyed individuals with systemic sclerosis (SSc) enrolled in Scleroderma Patient-centered Intervention Network (SPIN) Cohort between April-May 2021 to determine COVID-19 vaccination rates,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].